GlaxoSmithKline Pharmaceuticals Limited Announces Trading Window Closure for Q3 FY26 Results

GlaxoSmithKline Pharmaceuticals Limited has announced the closure of its trading window for buying or selling the company's shares. This closure is in compliance with the SEBI (Prohibition of Insider ...

GlaxoSmithKline Pharmaceuticals Limited has announced the closure of its trading window for buying or selling the company's shares. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The trading window will be closed from Thursday, 1st January 2026, until 48 hours after the announcement of the Unaudited Financial Results for the quarter and nine months ended 31st December 2025. The date of the Board Meeting to declare these financial results will be communicated in due course. The company has provided its contact details and CIN number as part of the filing.

Limitations of AI summaries

AI models can summarize market news but cannot assess portfolio-specific impact or simulate investment scenarios.

Platforms like Prysm provide stock-level and portfolio-level analysis.

Why is GlaxoSmithKline Pharmaceuticals Limited in the news today?

GlaxoSmithKline Pharmaceuticals Limited (GLAXO) is in the news due to the announcement is a routine regulatory disclosure regarding the closure of the trading window, which is standard practice before financial results are announced. it does not contain any new financial information or business updates that would indicate a positive or negative sentiment.

Trading Window Disclosure
GlaxoSmithKline Pharmaceuticals LimitedGLAXOhttps://prysm.fi/v2/analyze/GLAXO

AI-Powered Summary

Market Context

Top Queries

More News

Explore Prysm Tools

Related Stories

GlaxoSmithKline Pharmaceuticals Limited Announces Trading Window Closure for Q3 FY26 Results

December 23, 2025, 10:16 AM

AI Sentiment Analysis

Top Queries to Ask About GlaxoSmithKline Pharmaceuticals Limited

GlaxoSmithKline Pharmaceuticals Limited has announced the closure of its trading window for buying or selling the company's shares. This closure is in compliance with the SEBI (Prohibition of Insider Trading) Regulations, 2015.

The trading window will be closed from Thursday, 1st January 2026, until 48 hours after the announcement of the Unaudited Financial Results for the quarter and nine months ended 31st December 2025.

The date of the Board Meeting to declare these financial results will be communicated in due course. The company has provided its contact details and CIN number as part of the filing.

See What Deep Dive Gives You — in Seconds

“what happens when you click Deep Dive “

Instant AI Summary - “Get clean, noise-free earnings breakdowns.”

PDF Insights - “Download detailed, AI-generated reports.”

Metrics Explained -“Key ratios & trends explained in simple language.”

Want to know if this news pushes your stock up or down?

Just tap

deep dive

More News on GlaxoSmithKline Pharmaceuticals Limited

Discover more trending news on Prysm

View All